Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Olema Oncology

< Previous 1 2 3 Next >
Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Announces Expansion of Collaboration Agreement with Novartis
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Announces New Preclinical KAT6 Inhibitor Data to be Presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology to Participate in Upcoming Investor Conferences
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Announces Combined Financing for Up to $180 Million
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology to Present at the Canaccord Genuity 43rd Annual Growth Conference
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology to Present at the 2023 Jefferies Healthcare Conference
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Announces Upcoming Poster Presentation at the 2023 ESMO Breast Cancer Annual Congress
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology to Participate in Canaccord Genuity 2023 Horizons in Oncology Virtual Conference
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Strategic Update
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology to Present at Oppenheimer 33rd Annual Healthcare Conference
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology to Participate at Upcoming Investor Conferences
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology to Present at 41st Annual J.P. Morgan Healthcare Conference
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Announces OP-1250 Demonstrates Attractive Combinability with CDK 4/6 Inhibitor Palbociclib in Phase 1b Dose Escalation Study
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.